Cardio Diagnostics (NASDAQ:CDIO – Free Report) had its price target reduced by Benchmark from $4.00 to $1.35 in a research note issued to investors on Friday, Benzinga reports. They currently have a speculative buy rating on the stock.
Cardio Diagnostics Trading Down 13.9 %
Shares of NASDAQ CDIO opened at $0.75 on Friday. The stock has a 50 day simple moving average of $1.38 and a 200-day simple moving average of $1.53. Cardio Diagnostics has a 12-month low of $0.17 and a 12-month high of $3.56.
Hedge Funds Weigh In On Cardio Diagnostics
A hedge fund recently bought a new stake in Cardio Diagnostics stock. Vontobel Holding Ltd. acquired a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,000 shares of the company’s stock, valued at approximately $30,000. Vontobel Holding Ltd. owned 0.06% of Cardio Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Featured Stories
- Five stocks we like better than Cardio Diagnostics
- 3 Warren Buffett Stocks to Buy Now
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Merger or Not, Albertson’s Companies is a Good Buy
- 3 Stocks to Consider Buying in October
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.